One-year access to more than 500 world journals available in the system
-
http://medilib.ir
- Duration of Time : 365 Day
Price : 300$- Special Price : 100$
Antiphospholipid antibodies and COVID-19 thrombotic vasculopathy: one swallow does not make a summer
Pier Luigi Meroni, Maria Orietta Borghi
doi : 10.1136/annrheumdis-2021-220520
Annals of the Rheumatic Diseases 2021;80:1105-1107
Henrik Sjögren (1899–1986): the syndrome and his legacy
Roland Jonsson
doi : 10.1136/annrheumdis-2021-219942
Annals of the Rheumatic Diseases 2021;80:1108-1109
EULAR COVID-19 registry: lessons learnt and future considerations
Saskia Lawson-Tovey, Anja Strangfeld, Kimme L Hyrich, Loreto Carmona, Diana Rodrigues, Laure Gossec, Elsa F Mateus, Pedro M Machado
doi : 10.1136/annrheumdis-2021-220319
Annals of the Rheumatic Diseases 2021;80:1110-1115
EULAR Points to Consider (PtC) for designing, analysing and reporting of studies with work participation as an outcome domain in patients with inflammatory arthritis
Annelies Boonen, Polina Putrik, Mary Lucy Marques, Alessia Alunno, Lydia Abasolo, Dorcas Beaton, Neil Betteridge, Mathilda Bjørk, Maarten Boers, Boryana Boteva, Bruno Fautrel, Francis Guillemin, Elsa F Mateus, Elena Nikiphorou, Márta Péntek, Fernando Pimentel Santos, Johannes L Severens, Suzanne M M Verstappen, Karen Walker-Bone, Johan Karlsson Wallman, Marieke M ter Wee, René Westhovens, Sofia Ramiro
doi : 10.1136/annrheumdis-2020-219523
Annals of the Rheumatic Diseases 2021;80:1116-1123
Clinical studies with work participation (WP) as an outcome domain pose particular methodological challenges that hamper interpretation, comparison between studies and meta-analyses.
Glucocorticoid discontinuation in patients with early rheumatoid and undifferentiated arthritis: a post-hoc analysis of the BeSt and IMPROVED studies
Johanna Maria Maassen, Raquel Dos Santos Sobrín, Sytske Anne Bergstra, Robbert Goekoop, Tom W J Huizinga, Cornelia F Allaart
doi : 10.1136/annrheumdis-2021-220403
Annals of the Rheumatic Diseases 2021;80:1124-1129
To evaluate the success rate of glucocorticoid discontinuation and to study which factors are associated with successful discontinuation.
Efficacy and safety of tofacitinib versus baricitinib in patients with rheumatoid arthritis in real clinical practice: analyses with propensity score-based inverse probability of treatment weighting
Yusuke Miyazaki, Kazuhisa Nakano, Shingo Nakayamada, Satoshi Kubo, Yoshino Inoue, Yoshihisa Fujino, Yoshiya Tanaka
doi : 10.1136/annrheumdis-2020-219699
Annals of the Rheumatic Diseases 2021;80:1130-1136
The differences of efficacy between each Janus kinase (JAK) inhibitors have not been clarified in the patients with rheumatoid arthritis (RA) in clinical practice. Here, we compared the efficacy between tofacitinib (TOFA) and baricitinib (BARI) in clinical practice.
Associations of baseline use of biologic or targeted synthetic DMARDs with COVID-19 severity in rheumatoid arthritis: Results from the COVID-19 Global Rheumatology Alliance physician registry
Jeffrey A Sparks, Zachary S Wallace, Andrea M Seet, Milena A Gianfrancesco, Zara Izadi, Kimme L Hyrich, Anja Strangfeld, Laure Gossec, Loreto Carmona, Elsa F Mateus, Saskia Lawson-Tovey, Laura Trupin, Stephanie Rush, Patricia Katz, Gabriela Schmajuk, Lindsay Jacobsohn, Leanna Wise, Emily L Gilbert, Ali Duarte-García, Maria O Valenzuela-Almada, Guillermo J Pons-Estel, Carolina A Isnardi, Guillermo A Berbotto, Tiffany Y -T Hsu, Kristin M D’Silva, Naomi J Patel, Lianne Kearsley-Fleet, Martin Schäfer, Sandra Lúcia Euzébio Ribeiro, Samar Al Emadi, Liselotte Tidblad, Carlo Alberto Scirè, Bernd Raffeiner, Thierry Thomas, René-Marc Flipo, Jérôme Avouac, Raphaèle Seror, Miguel Bernardes, Maria Margarida Cunha, Rebecca Hasseli, Hendrik Schulze-Koops, Ulf Müller-Ladner, Christof Specker, Viviane Angelina de Souza, Licia Maria Henrique da Mota, Ana Paula Monteiro Gomides, Philippe Dieudé, Elena Nikiphorou, Vanessa L Kronzer, Namrata Singh, Manuel F Ugarte-Gil, Beth Wallace, Akpabio Akpabio, Ranjeny Thomas, Suleman Bhana, Wendy Costello, Rebecca Grainger, Jonathan S Hausmann, Jean W Liew, Emily Sirotich, Paul Sufka, Philip C Robinson, Pedro M Machado, Jinoos Yazdany
doi : 10.1136/annrheumdis-2021-220418
Annals of the Rheumatic Diseases 2021;80:1137-1146
To investigate baseline use of biologic or targeted synthetic (b/ts) disease-modifying antirheumatic drugs (DMARDs) and COVID-19 outcomes in rheumatoid arthritis (RA).
Efficacy and safety of tildrakizumab in patients with active psoriatic arthritis: results of a randomised, double-blind, placebo-controlled, multiple-dose, 52-week phase IIb study
Philip J Mease, Saima Chohan, Ferran J Garcia Fructuoso, Michael E Luggen, Proton Rahman, Siba P Raychaudhuri, Richard C Chou, Alan M Mendelsohn, Stephen J Rozzo, Alice Gottlieb
doi : 10.1136/annrheumdis-2020-219014
Annals of the Rheumatic Diseases 2021;80:1147-1157
To evaluate efficacy and safety of the anti-interleukin-23p19 monoclonal antibody tildrakizumab in patients with psoriatic arthritis (PsA).
Safety and efficacy of faecal microbiota transplantation for active peripheral psoriatic arthritis: an exploratory randomised placebo-controlled trial
Maja Skov Kragsnaes, Jens Kjeldsen, Hans Christian Horn, Heidi Lausten Munk, Jens Kristian Pedersen, Søren Andreas Just, Palle Ahlquist, Finn Moeller Pedersen, Maarten de Wit, Sören Möller, Vibeke Andersen, Karsten Kristiansen, Dorte Kinggaard Holm, Hanne Marie Holt, Robin Christensen, Torkell Ellingsen
doi : 10.1136/annrheumdis-2020-219511
Annals of the Rheumatic Diseases 2021;80:1158-1167
Although causality remains to be established, targeting dysbiosis of the intestinal microbiota by faecal microbiota transplantation (FMT) has been proposed as a novel treatment for inflammatory diseases. In this exploratory, proof-of-concept study, we evaluated the safety and efficacy of FMT in psoriatic arthritis (PsA).
Polygenic Risk Scores have high diagnostic capacity in ankylosing spondylitis
Zhixiu Li, Xin Wu, Paul J Leo, Erika De Guzman, Nurullah Akkoc, Maxime Breban, Gary J Macfarlane, Mahdi Mahmoudi, Helena Marzo-Ortega, Lisa K Anderson, Lawrie Wheeler, Chung-Tei Chou, Andrew A Harrison, Simon Stebbings, Gareth T Jones, So-Young Bang, Geng Wang, Ahmadreza Jamshidi, Elham Farhadi, Jing Song, Li Lin, Mengmeng Li, James Cheng-Chung Wei, Nicholas G Martin, Margaret J Wright, MinJae Lee, Yuqin Wang, Jian Zhan, Jin-San Zhang, Xiaobing Wang, Zi-Bing Jin, Michael H Weisman, Lianne S Gensler, Michael M Ward, Mohammad Hossein Rahbar, Laura Diekman, Tae-Hwan Kim, John D Reveille, Bryan Paul Wordsworth, Huji Xu, Matthew A Brown
doi : 10.1136/annrheumdis-2020-219446
Annals of the Rheumatic Diseases 2021;80:1168-1174
We sought to test the hypothesis that Polygenic Risk Scores (PRSs) have strong capacity to discriminate cases of ankylosing spondylitis (AS) from healthy controls and individuals in the community with chronic back pain.
Quality indicators for systemic lupus erythematosus based on the 2019 EULAR recommendations: development and initial validation in a cohort of 220 patients
Katerina Chavatza, Myrto Kostopoulou, Dionysis Nikolopoulos, Ourania Gioti, Konstantina Togia, Laura Andreoli, Martin Aringer, John Boletis, Andrea Doria, Frederic A Houssiau, David Jayne, Marta Mosca, Elisabet Svenungsson, Angela Tincani, George Bertsias, Antonis Fanouriakis, Dimitrios T Boumpas
doi : 10.1136/annrheumdis-2021-220438
Annals of the Rheumatic Diseases 2021;80:1175-1182
Quality of care is receiving increased attention in systemic lupus erythematosus (SLE). We developed quality indicators (QIs) for SLE based on the 2019 update of European League Against Rheumatism recommendations.
Interaction between the STAT4 rs11889341(T) risk allele and smoking confers increased risk of myocardial infarction and nephritis in patients with systemic lupus erythematosus
Sarah Reid, Niklas Hagberg, Johanna K Sandling, Andrei Alexsson, Pascal Pucholt, Christopher Sjöwall, Karoline Lerang, Andreas Jönsen, Iva Gunnarsson, Ann-Christine Syvänen, Anne Margrethe Troldborg, Anne Voss, Anders A Bengtsson, Øyvind Molberg, Søren Jacobsen, Elisabet Svenungsson, Lars Rönnblom, Dag Leonard
doi : 10.1136/annrheumdis-2020-219727
Annals of the Rheumatic Diseases 2021;80:1183-1189
To investigate how genetics influence the risk of smoking-related systemic lupus erythematosus (SLE) manifestations.
B cell subset composition segments clinically and serologically distinct groups in chronic cutaneous lupus erythematosus
Scott A Jenks, Chungwen Wei, Regina Bugrovsky, Aisha Hill, Xiaoqian Wang, Francesca M Rossi, Kevin Cashman, Matthew C Woodruff, Laura D Aspey, S. Sam Lim, Gaobin Bao, Cristina Drenkard, Ignacio Sanz
doi : 10.1136/annrheumdis-2021-220349
Annals of the Rheumatic Diseases 2021;80:1190-1200
While the contribution of B-cells to SLE is well established, its role in chronic cutaneous lupus erythematosus (CCLE) remains unclear. Here, we compare B-cell and serum auto-antibody profiles between patients with systemic lupus erythematosus (SLE), CCLE, and overlap conditions.
Immune response to dermatomyositis-specific autoantigen, transcriptional intermediary factor 1? can result in experimental myositis
Naoko Okiyama, Yuki Ichimura, Miwako Shobo, Ryota Tanaka, Noriko Kubota, Akimasa Saito, Yosuke Ishitsuka, Rei Watanabe, Yasuhiro Fujisawa, Yoshiyuki Nakamura, Akihiro Murakami, Hisako Kayama, Kiyoshi Takeda, Manabu Fujimoto
doi : 10.1136/annrheumdis-2020-218661
Annals of the Rheumatic Diseases 2021;80:1201-1208
To investigate whether autoimmunity to transcriptional intermediary factor 1 (TIF1)?, a ubiquitous nuclear autoantigen for myositis-specific autoantibodies detected in patients with dermatomyositis (DM) is pathogenetic for inflammatory myopathy.
circPDE4B prevents articular cartilage degeneration and promotes repair by acting as a scaffold for RIC8A and MID1
Shuying Shen, Yute Yang, Panyang Shen, Jun Ma, Bin Fang, Qingxin Wang, Kefan Wang, Peihua Shi, Shunwu Fan, Xiangqian Fang
doi : 10.1136/annrheumdis-2021-219969
Annals of the Rheumatic Diseases 2021;80:1209-1219
Circular RNAs (circRNAs) have emerged as significant biological regulators. Herein, we aimed to elucidate the role of an unidentified circRNA (circPDE4B) that is reportedly downregulated in osteoarthritis (OA) tissues.
Variants in urate transporters, ADH1B, GCKR and MEPE genes associate with transition from asymptomatic hyperuricaemia to gout: results of the first gout versus asymptomatic hyperuricaemia GWAS in Caucasians using data from the UK Biobank
Gabriela Sandoval-Plata, Kevin Morgan, Abhishek Abhishek
doi : 10.1136/annrheumdis-2020-219796
Annals of the Rheumatic Diseases 2021;80:1220-1226
To perform a genome-wide association study (GWAS) of gout cases versus asymptomatic hyperuricaemia (AH) controls, and gout cases versus normouricaemia controls, and to generate a polygenic risk score (PRS) to determine gout-case versus AH-control status.
Genome-wide association study identifies RNF123 locus as associated with chronic widespread musculoskeletal pain
Md Shafiqur Rahman, Bendik S Winsvold, Sergio O Chavez Chavez, Sigrid Børte, Yakov A Tsepilov, Sodbo Zh Sharapov, HUNT All-In Pain, Yurii S Aulchenko, Knut Hagen, Egil A Fors, Kristian Hveem, John Anker Zwart, Joyce B van Meurs, Maxim B Freidin, Frances MK Williams
doi : 10.1136/annrheumdis-2020-219624
Annals of the Rheumatic Diseases 2021;80:1227-1235
Chronic widespread musculoskeletal pain (CWP) is a symptom of fibromyalgia and a complex trait with poorly understood pathogenesis. CWP is heritable (48%–54%), but its genetic architecture is unknown and candidate gene studies have produced inconsistent results. We conducted a genome-wide association study to get insight into the genetic background of CWP.
Anticardiolipin and other antiphospholipid antibodies in critically ill COVID-19 positive and negative patients
Uriel Trahtemberg, Robert Rottapel, Claudia C Dos Santos, Arthur S Slutsky, Andrew Baker, Marvin J Fritzler
doi : 10.1136/annrheumdis-2021-220206
Annals of the Rheumatic Diseases 2021;80:1236-1240
Reports of severe COVID-19 being associated with thrombosis, antiphospholipid antibodies (APLA), and antiphospholipid syndrome have yielded disparate conclusions. Studies comparing patients with COVID-19 with contemporaneous controls of similar severity are lacking.
Challenges in the diagnosis of early rheumatoid arthritis in times of COVID-19
Bernardo D'Onofrio, Ludovico De Stefano, Bianca Lucia Palermo, Blerina Xoxi, Antonio Manzo, Carlomaurizio Montecucco, Serena Bugatti
doi : 10.1136/annrheumdis-2021-220219
Annals of the Rheumatic Diseases 2021;80:1242-1243
Ensuring tight control in patients with rheumatoid arthritis treated with targeted therapies during the COVID-19 pandemic using a telehealth strategy
Francesca Ingegnoli, Gilberto Cincinelli, Angela Flavia Luppino, Ennio Giulio Favalli, Annalisa Orenti, Patrizia Boracchi, Roberto Caporali
doi : 10.1136/annrheumdis-2021-220142
Annals of the Rheumatic Diseases 2021;80:1243-1245
Use of Janus kinase inhibitors in COVID-19: a prospective observational series in 522 individuals
Oleg Melikhov, Tatiana Kruglova, Karine Lytkina, Georgy Melkonyan, Elena Prokhorovich, Gleb Putsman, Grigory Rodoman, Arkady Vertkin, Alena Zagrebneva, Justin Stebbing
doi : 10.1136/annrheumdis-2021-220049
Annals of the Rheumatic Diseases 2021;80:1245-1246
Microarray evaluation of allergen-specific IgE in eosinophilic granulomatosis with polyangiitis
Federica Bello, Federica Maritati, Antonella Radice, Renato Alberto Sinico, Giacomo Emmi, Augusto Vaglio
doi : 10.1136/annrheumdis-2021-220111
Annals of the Rheumatic Diseases 2021;80:1247-1248
Medications associated with fracture risk in patients with rheumatoid arthritis
Yi-Sheng Liou, Tsung-Kun Lin, Hung-Yi Chen, Gwo-Ping Jong
doi : 10.1136/annrheumdis-2019-216262
Annals of the Rheumatic Diseases 2021;80:e140
Response to: ‘Medications associated with fracture risk in patients with rheumatoid arthritis’ by Chen et al
Gulsen Ozen, Kaleb Michaud
doi : 10.1136/annrheumdis-2019-216293
Annals of the Rheumatic Diseases 2021;80:e141
Diabetes mellitus in ankylosing spondylitis
Young Ho Lee, Gwan Gyu Song
doi : 10.1136/annrheumdis-2019-216335
Annals of the Rheumatic Diseases 2021;80:e142
Response to: ‘Diabetes mellitus in ankylosing spondylitis’ by Lee and Song
Shih-Wei Lai, Yu-Hung Kuo, Kuan-Fu Liao
doi : 10.1136/annrheumdis-2019-216429
Annals of the Rheumatic Diseases 2021;80:e143
Incidence of inflammatory bowel disease in patients with ankylosing spondylitis
Shih-Wei Lai, Yu-Hung Kuo, Kuan-Fu Liao
doi : 10.1136/annrheumdis-2019-216362
Annals of the Rheumatic Diseases 2021;80:e144
Application of MS score in macrophage activation syndrome patients associated with adult onset Still’s disease
Ran Wang, Ting Li, Shuang Ye, Wenefng Tan, Cheng Zhao, Yisha Li, Chunde Bao, Qiong Fu
doi : 10.1136/annrheumdis-2019-216286
Annals of the Rheumatic Diseases 2021;80:e145
Response to ‘Application of MS score in macrophage activation syndrome patients associated with adult onset Still’s disease’ by Wang et al
Francesca Minoia, Angelo Ravelli
doi : 10.1136/annrheumdis-2019-216310
Annals of the Rheumatic Diseases 2021;80:e146
Overlap of systemic lupus erythematosus and myositis is rare in anti-Ku antibody-positive patients
Mariko Ogawa-Momohara, Yoshinao Muro, Masashi Akiyama
doi : 10.1136/annrheumdis-2019-216375
Annals of the Rheumatic Diseases 2021;80:e147
Response to: ‘Overlap of systemic lupus erythematosus and myositis is rare in anti-Ku antibody-positive patients’ by Ogawa-Momohara et al
Lionel Spielmann, Benoit Nespola, Alain Meyer
doi : 10.1136/annrheumdis-2019-216413
Annals of the Rheumatic Diseases 2021;80:e148
In search for the ideal anatomical composition of vascularised human skin equivalents for systemic sclerosis translational research: should we recruit the telocytes?
Mirko Manetti, Marco Matucci-Cerinic
doi : 10.1136/annrheumdis-2019-216371
Annals of the Rheumatic Diseases 2021;80:e149
Response to: ‘In search for the ideal anatomical composition of vascularised human skin equivalents for systemic sclerosis translational research: should we recruit the telocytes?’ by Manetti and Matucci-Cerinic
Alexandru Emil Matei, Jörg H W Distler
doi : 10.1136/annrheumdis-2019-216393
Annals of the Rheumatic Diseases 2021;80:e150
Association of anti-Ro52 autoantibodies with interstitial lung disease in connective tissue diseases
Si Wu, Xiaojun Tang, Liping Wu, Liang-jing Lu, Xuebing Feng
doi : 10.1136/annrheumdis-2019-216372
Annals of the Rheumatic Diseases 2021;80:e151
NLRP12 gene mutation in India: case finding and diagnosis made easy in the days of whole exome sequencing
Kanjaksha Ghosh
doi : 10.1136/annrheumdis-2019-216270
Annals of the Rheumatic Diseases 2021;80:e152
Correction: First external validation of sensitivity and specificity of the European League Against Rheumatism (EULAR)/American College of Rheumatology (ACR) classification criteria for idiopathic inflammatory myopathies with a Japanese cohort
doi : 10.1136/annrheumdis-2019-215488corr1
Annals of the Rheumatic Diseases 2021;80:e153
Correction: New composite endpoint in early diffuse cutaneous systemic sclerosis: revisiting the provisional American College of Rheumatology Composite Response Index in Systemic Sclerosis
doi : 10.1136/annrheumdis-2020-219100corr1
Annals of the Rheumatic Diseases 2021;80:e154
Correction: EULAR recommendations for the reporting of ultrasound studies in rheumatic and musculoskeletal diseases (RMDs)
doi : 10.1136/annrheumdis-2020-219816corr1
Annals of the Rheumatic Diseases 2021;80:e155
